NXGL
NEXGEL, Inc.
Medical - Instruments & Supplies
Market Cap$5M
5Y Perf.-77.3%
Compare Stocks
5 / 10Try these comparisons:
Stock Comparison
NXGL vs LIQT vs XTLB vs BFRI vs SKIN
Revenue, margins, valuation, and 5-year total return — side by side.
LIQT
LiqTech International, Inc.
Industrial - Pollution & Treatment Controls
Market Cap$22M
5Y Perf.-95.0%
XTLB
XTL Biopharmaceuticals Ltd.
Biotechnology
Market Cap$294K
5Y Perf.-77.1%
BFRI
Biofrontera Inc.
Drug Manufacturers - Specialty & Generic
Market Cap$13M
5Y Perf.-99.2%
SKIN
The Beauty Health Company
Household & Personal Products
Market Cap$118M
5Y Perf.-97.6%
NXGL vs LIQT vs XTLB vs BFRI vs SKIN — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | NXGL | LIQT | XTLB | BFRI | SKIN |
|---|---|---|---|---|---|
| Industry | Medical - Instruments & Supplies | Industrial - Pollution & Treatment Controls | Biotechnology | Drug Manufacturers - Specialty & Generic | Household & Personal Products |
| Market Cap | $5M | $22M | $294K | $13M | $118M |
| Revenue (TTM) | $12M | $17M | $451K | $42M | $296M |
| Net Income (TTM) | $-3M | $-9M | $-1M | $-11M | $-6M |
| Gross Margin | 38.3% | 4.9% | 26.4% | 75.8% | 64.9% |
| Operating Margin | -25.5% | -50.0% | -481.6% | -27.2% | -3.6% |
| Total Debt | $3M | $12M | $138K | $6M | $379M |
| Cash & Equiv. | $2M | — | $371K | $6M | $233M |
NXGL vs LIQT vs XTLB vs BFRI vs SKIN — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
NXGL
LIQT
XTLB
BFRI
SKIN
| Stock | Dec 21 | May 26 | Return |
|---|---|---|---|
| NEXGEL, Inc. (NXGL) | 100 | 22.7 | -77.3% |
| LiqTech Internation… (LIQT) | 100 | 5.0 | -95.0% |
| XTL Biopharmaceutic… (XTLB) | 100 | 22.9 | -77.1% |
| Biofrontera Inc. (BFRI) | 100 | 0.8 | -99.2% |
| The Beauty Health C… (SKIN) | 100 | 2.4 | -97.6% |
Price return only. Dividends and distributions are not included.
Quick Verdict: NXGL vs LIQT vs XTLB vs BFRI vs SKIN
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: LIQT and SKIN are tied at the top with 2 categories each (5-stock set) — the right choice depends on your priorities. The Beauty Health Company is the stronger pick specifically for profitability and margin quality and operational efficiency and capital deployment. NXGL also leads in specific categories worth noting. This set spans 3 sectors — these stocks serve different portfolio roles, not just different price points.
NXGL
NEXGEL, Inc.
The Growth Play
NXGL ranks third and is worth considering specifically for growth exposure and long-term compounding.
- Rev growth 112.5%, EPS growth 10.7%, 3Y rev CAGR 77.6%
- -82.5% 10Y total return vs XTLB's -87.3%
- Lower volatility, beta 0.91, Low D/E 46.5%, current ratio 2.07x
- Beta 0.91, current ratio 2.07x
Best for: growth exposure and long-term compounding
LIQT
LiqTech International, Inc.
The Income Pick
LIQT carries the broadest edge in this set and is the clearest fit for income & stability.
- beta 0.52
- Beta 0.52 vs SKIN's 2.00, lower leverage
- +64.8% vs NXGL's -76.3%
Best for: income & stability
XTLB
XTL Biopharmaceuticals Ltd.
The Healthcare Pick
XTLB lags the leaders in this set but could rank higher in a more targeted comparison.
Best for: healthcare exposure
BFRI
Biofrontera Inc.
The Healthcare Pick
Among these 5 stocks, BFRI doesn't own a clear edge in any measured category.
Best for: healthcare exposure
SKIN
The Beauty Health Company
The Quality Compounder
SKIN is the #2 pick in this set and the best alternative if quality and efficiency is your priority.
- -2.0% margin vs XTLB's -227.7%
- -1.2% ROA vs BFRI's -52.2%, ROIC -6.8% vs -124.3%
Best for: quality and efficiency
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | NXGL | 112.5% revenue growth vs XTLB's -173.2% |
| Quality / Margins | SKIN | -2.0% margin vs XTLB's -227.7% |
| Stability / Safety | LIQT | Beta 0.52 vs SKIN's 2.00, lower leverage |
| Dividends | Tie | None of these 5 stocks pay a meaningful dividend |
| Momentum (1Y) | LIQT | +64.8% vs NXGL's -76.3% |
| Efficiency (ROA) | SKIN | -1.2% ROA vs BFRI's -52.2%, ROIC -6.8% vs -124.3% |
NXGL vs LIQT vs XTLB vs BFRI vs SKIN — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
FY 2024
FY 2024
Segment breakdown not available.
FY 2023
FY 2025
NXGL vs LIQT vs XTLB vs BFRI vs SKIN — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLSKINLAGGINGBFRI
Who Leads Where
SKIN leads in 2 of 6 categories
LIQT leads 1 • NXGL leads 0 • XTLB leads 0 • BFRI leads 0 • 2 tied
Explore the data ↓BFRIBiofrontera Inc.
0leads
XTLBXTL Biopharmaceutical…
0leads
NXGLNEXGEL, Inc.
0leads
LIQTLiqTech International…
1leads
SKINThe Beauty Health Com…
2leads
6 Total Categories
CATEGORYLEADERvs LIQTvs NXGLMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
SKIN3/6
Valuation MetricsMultiples, price ratios, and targets
Tied
—
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
SKIN6/9
Total Returns1Y, 3Y, 5Y total returns with dividends
LIQT3/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
SKIN leads this category, winning 3 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
SKIN is the larger business by revenue, generating $296M annually — 656.6x XTLB's $451,000. Profitability is closely matched — net margins range from -2.0% (SKIN) to -2.3% (XTLB). On growth, LIQT holds the edge at +53.6% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | NXGLNEXGEL, Inc. | LIQTLiqTech Internati… | XTLBXTL Biopharmaceut… | BFRIBiofrontera Inc. | SKINThe Beauty Health… |
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $12M | $17M | $451,000 | $42M | $296M |
| EBITDAEarnings before interest/tax | -$2M | -$6M | -$1M | -$11M | $9M |
| Net IncomeAfter-tax profit | -$3M | -$9M | -$1M | -$11M | -$6M |
| Free Cash FlowCash after capex | -$3M | -$7M | $0 | -$13M | $29M |
| Gross MarginGross profit ÷ Revenue | +38.3% | +4.9% | +26.4% | +75.8% | +64.9% |
| Operating MarginEBIT ÷ Revenue | -25.5% | -50.0% | -4.8% | -27.2% | -3.6% |
| Net MarginNet income ÷ Revenue | -24.7% | -53.3% | -2.3% | -25.3% | -2.0% |
| FCF MarginFCF ÷ Revenue | -21.8% | -39.3% | -3.7% | -32.0% | +9.8% |
| Rev. Growth (YoY)Latest quarter vs prior year | -0.2% | +53.6% | — | +36.2% | -6.7% |
| EPS Growth (YoY)Latest quarter vs prior year | +27.3% | +69.4% | +20.0% | +100.0% | +38.0% |
SKIN leads this category, winning 3 of 6 comparable metrics.
Valuation Metrics
Evenly matched — XTLB and BFRI and SKIN each lead in 1 of 3 comparable metrics.
Valuation Metrics
| Metric | NXGLNEXGEL, Inc. | LIQTLiqTech Internati… | XTLBXTL Biopharmaceut… | BFRIBiofrontera Inc. | SKINThe Beauty Health… |
|---|---|---|---|---|---|
| Market CapShares × price | $5M | $22M | $293,767 | $13M | $118M |
| Enterprise ValueMkt cap + debt − cash | $6M | $34M | $60,767 | $13M | $264M |
| Trailing P/EPrice ÷ TTM EPS | -1.23x | -2.59x | -0.28x | — | -5.69x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — | — | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — | — | — | — |
| EV / EBITDAEnterprise value multiple | — | — | — | — | 7331.15x |
| Price / SalesMarket cap ÷ Revenue | 0.58x | 1.35x | 0.65x | 0.32x | 0.39x |
| Price / BookPrice ÷ Book value/share | 0.66x | 2.14x | 0.05x | — | 2.02x |
| Price / FCFMarket cap ÷ FCF | — | — | — | — | 3.17x |
Evenly matched — XTLB and BFRI and SKIN each lead in 1 of 3 comparable metrics.
Profitability & Efficiency
SKIN leads this category, winning 6 of 9 comparable metrics.
Profitability & Efficiency
SKIN delivers a -9.4% return on equity — every $100 of shareholder capital generates $-9 in annual profit, vs $-11 for BFRI. XTLB carries lower financial leverage with a 0.03x debt-to-equity ratio, signaling a more conservative balance sheet compared to SKIN's 6.20x. On the Piotroski fundamental quality scale (0–9), SKIN scores 7/9 vs LIQT's 2/9, reflecting strong financial health.
| Metric | NXGLNEXGEL, Inc. | LIQTLiqTech Internati… | XTLBXTL Biopharmaceut… | BFRIBiofrontera Inc. | SKINThe Beauty Health… |
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | -51.7% | -70.0% | -25.5% | -11.4% | -9.4% |
| ROA (TTM)Return on assets | -26.9% | -29.5% | -17.7% | -52.2% | -1.2% |
| ROICReturn on invested capital | -43.1% | -31.1% | -54.1% | -124.3% | -6.8% |
| ROCEReturn on capital employed | -44.7% | — | -50.7% | -84.8% | -4.5% |
| Piotroski ScoreFundamental quality 0–9 | 4 | 2 | 3 | 4 | 7 |
| Debt / EquityFinancial leverage | 0.46x | 1.17x | 0.03x | 0.59x | 6.20x |
| Net DebtTotal debt minus cash | $1M | $12M | -$233,000 | -$231,000 | $146M |
| Cash & Equiv.Liquid assets | $2M | — | $371,000 | $6M | $233M |
| Total DebtShort + long-term debt | $3M | $12M | $138,000 | $6M | $379M |
| Interest CoverageEBIT ÷ Interest expense | -40.04x | -13.46x | -13.31x | -69.93x | 0.81x |
SKIN leads this category, winning 6 of 9 comparable metrics.
Total Returns (Dividends Reinvested)
LIQT leads this category, winning 3 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in XTLB five years ago would be worth $1,963 today (with dividends reinvested), compared to $129 for BFRI. Over the past 12 months, LIQT leads with a +64.8% total return vs NXGL's -76.3%. The 3-year compound annual growth rate (CAGR) favors LIQT at -11.8% vs SKIN's -56.4% — a key indicator of consistent wealth creation.
| Metric | NXGLNEXGEL, Inc. | LIQTLiqTech Internati… | XTLBXTL Biopharmaceut… | BFRIBiofrontera Inc. | SKINThe Beauty Health… |
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | -66.0% | +54.9% | +11.3% | +57.2% | -35.0% |
| 1-Year ReturnPast 12 months | -76.3% | +64.8% | -50.9% | +62.5% | -35.9% |
| 3-Year ReturnCumulative with dividends | -58.4% | -31.3% | -45.7% | -90.5% | -91.7% |
| 5-Year ReturnCumulative with dividends | -82.5% | -96.1% | -80.4% | -98.7% | -92.9% |
| 10-Year ReturnCumulative with dividends | -82.5% | -90.9% | -87.3% | -98.7% | -91.6% |
| CAGR (3Y)Annualised 3-year return | -25.4% | -11.8% | -18.4% | -54.4% | -56.4% |
LIQT leads this category, winning 3 of 6 comparable metrics.
Risk & Volatility
Evenly matched — LIQT and BFRI each lead in 1 of 2 comparable metrics.
Risk & Volatility
LIQT is the less volatile stock with a 0.52 beta — it tends to amplify market swings less than SKIN's 2.00 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. BFRI currently trades 95.8% from its 52-week high vs NXGL's 20.7% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | NXGLNEXGEL, Inc. | LIQTLiqTech Internati… | XTLBXTL Biopharmaceut… | BFRIBiofrontera Inc. | SKINThe Beauty Health… |
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.85x | 0.54x | 1.64x | 1.67x | 1.71x |
| 52-Week HighHighest price in past year | $2.97 | $3.35 | $10.28 | $1.19 | $2.69 |
| 52-Week LowLowest price in past year | $0.56 | $1.30 | $1.05 | $0.54 | $0.76 |
| % of 52W HighCurrent price vs 52-week peak | +20.7% | +68.9% | +26.0% | +95.8% | +33.8% |
| RSI (14)Momentum oscillator 0–100 | 43.3 | 57.0 | 57.0 | 63.6 | 52.1 |
| Avg Volume (50D)Average daily shares traded | 370K | 50K | 2.4M | 122K | 760K |
Evenly matched — LIQT and BFRI each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
| Metric | NXGLNEXGEL, Inc. | LIQTLiqTech Internati… | XTLBXTL Biopharmaceut… | BFRIBiofrontera Inc. | SKINThe Beauty Health… |
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | — | — | — | Hold |
| Price TargetConsensus 12-month target | — | — | — | — | $1.30 |
| # AnalystsCovering analysts | — | — | — | — | 13 |
| Dividend YieldAnnual dividend ÷ price | — | — | — | — | — |
| Dividend StreakConsecutive years of raises | — | — | — | — | — |
| Dividend / ShareAnnual DPS | — | — | — | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
SKIN leads in 2 of 6 categories (Income & Cash Flow, Profitability & Efficiency). LIQT leads in 1 (Total Returns). 2 tied.
Best OverallThe Beauty Health Company (SKIN)Leads 2 of 6 categories
Loading custom metrics...
NXGL vs LIQT vs XTLB vs BFRI vs SKIN: Key Questions Answered
8 questions · data-driven answers · updated daily
01Is NXGL or LIQT or XTLB or BFRI or SKIN a better buy right now?
For growth investors, NEXGEL, Inc.
(NXGL) is the stronger pick with 112. 5% revenue growth year-over-year, versus -10. 0% for The Beauty Health Company (SKIN). Analysts rate The Beauty Health Company (SKIN) a "Hold" — based on 13 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — NXGL or LIQT or XTLB or BFRI or SKIN?
Over the past 5 years, XTL Biopharmaceuticals Ltd.
(XTLB) delivered a total return of -80. 4%, compared to -98. 7% for Biofrontera Inc. (BFRI). Over 10 years, the gap is even starker: NXGL returned -83. 1% versus BFRI's -98. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — NXGL or LIQT or XTLB or BFRI or SKIN?
By beta (market sensitivity over 5 years), LiqTech International, Inc.
(LIQT) is the lower-risk stock at 0. 54β versus The Beauty Health Company's 1. 71β — meaning SKIN is approximately 217% more volatile than LIQT relative to the S&P 500. On balance sheet safety, XTL Biopharmaceuticals Ltd. (XTLB) carries a lower debt/equity ratio of 3% versus 6% for The Beauty Health Company — giving it more financial flexibility in a downturn.
04Which is growing faster — NXGL or LIQT or XTLB or BFRI or SKIN?
By revenue growth (latest reported year), NEXGEL, Inc.
(NXGL) is pulling ahead at 112. 5% versus -10. 0% for The Beauty Health Company (SKIN). On earnings-per-share growth, the picture is similar: Biofrontera Inc. grew EPS 100. 0% year-over-year, compared to 10. 7% for NEXGEL, Inc.. Over a 3-year CAGR, NXGL leads at 77. 6% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — NXGL or LIQT or XTLB or BFRI or SKIN?
The Beauty Health Company (SKIN) is the more profitable company, earning -3.
2% net margin versus -227. 7% for XTL Biopharmaceuticals Ltd. — meaning it keeps -3. 2% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: SKIN leads at -6. 9% versus -481. 6% for XTLB. At the gross margin level — before operating expenses — BFRI leads at 75. 8%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — NXGL or LIQT or XTLB or BFRI or SKIN?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is NXGL or LIQT or XTLB or BFRI or SKIN better for a retirement portfolio?
For long-horizon retirement investors, LiqTech International, Inc.
(LIQT) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 54)). The Beauty Health Company (SKIN) carries a higher beta of 1. 71 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (LIQT: -91. 0%, SKIN: -94. 6%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between NXGL and LIQT and XTLB and BFRI and SKIN?
These companies operate in different sectors (NXGL (Healthcare) and LIQT (Industrials) and XTLB (Healthcare) and BFRI (Healthcare) and SKIN (Consumer Defensive)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.
In terms of investment character: NXGL is a small-cap high-growth stock; LIQT is a small-cap quality compounder stock; XTLB is a small-cap quality compounder stock; BFRI is a small-cap quality compounder stock; SKIN is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
Revenue Growth>
%
(NXGL: -0.2% · LIQT: 53.6%)You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.